Identification of the precursor protein for the heparan sulfate proteoglycan of human colon carcinoma cells and its post-translational modifications.
Human colon carcinoma cells synthesize a high-molecular-weight heparan sulfate proteoglycan which is localized at the cell surface. In this study we have performed a series of immunoprecipitation and pulse-chase experiments associated with various pharmacological agents that interfere with the synthesis and post-translational modification of the proteoglycan. We demonstrate that colon carcinoma cells synthesize the heparan sulfate proteoglycan from a 400-kDa precursor protein that is immunologically related to the Engelbreth-Holm-Swarm (EHS) tumor cell proteoglycan. The cells contain a large pool of precursor protein with a half-life of about 75 min. Most of the precursor protein receives heparan sulfate side chains and is then transported to the cell surface and released into the medium. A portion of the precursor pool, however, does not receive heparan sulfate chains but is secreted into the medium. The glycosylation and subsequent secretion of the 400-kDa precursor protein was inhibited by NH4Cl and even more by monensin, indicating that the transit of precursor from the rough endoplasmic reticulum to the cell surface occurred through the Golgi complex and acidic compartments. The existence of a sizable pool of precursor protein was confirmed by additional experiments using cycloheximide and xyloside. These experiments showed that the half-life of the precursor protein was also 75 min and that stimulation of heparan sulfate synthesis by xyloside was greatly enhanced (about 12-fold) after new protein core synthesis was blocked by cycloheximide. Although the structural models proposed for the EHS and colon carcinoma heparan sulfate proteoglycans differ, the observation that they are derived from a precursor protein with dimensional and immunological similarities suggests that they may be genetically related.
Iozzo
R V
RV
Department of Pathology and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
Hassell
J R
JR
D000643:Ammonium Chloride; D015153:Blotting, Western; D002277:Carcinoma / Q000032:analysis; D002460:Cell Line; D011508:Chondroitin Sulfate Proteoglycans / Q000302:isolation & purification* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000032:analysis; D003513:Cycloheximide; D006025:Glycosaminoglycans / Q000302:isolation & purification*; D006027:Glycosides; D006497:Heparan Sulfate / Q000302:isolation & purification* / Q000378:metabolism; D006801:Humans; D008985:Monensin; D011133:Polysaccharide-Lyases; D011233:Precipitin Tests; D011498:Protein Precursors / Q000302:isolation & purification* / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011509:Proteoglycans / Q000302:isolation & purification*; D014357:Trypsin
D000643:Ammonium Chloride; D011508:Chondroitin Sulfate Proteoglycans; D003513:Cycloheximide; D006025:Glycosaminoglycans; D006027:Glycosides; D006497:Heparan Sulfate; D008985:Monensin; D011133:Polysaccharide-Lyases; D011498:Protein Precursors; D011509:Proteoglycans; D014357:Trypsin; C010807:xylosides; C021349:heparitinsulfate lyase